ISHLT 2022: Clinical Variables in Predicting Survival and Hospitalization for Pulmonary Arterial Hypertension Using Harmonized Data

Liu, Z., An, H.,Lin, S., Kraisangka, J., Correa-Jaque, P., Webb, A., Tiwari, H., Wiener, H., Benza, R. “Clinical Variables in Predicting Survival and Hospitalization for Pulmonary Arterial Hypertension Using Harmonized Data.” The Journal of Heart and Lung Transplantation, vol. 41, no. 4, Apr. 2022, pp. S34–35. Purpose: Pulmonary arterial hypertension (PAH) is a type of […]

AHA 2021: Association of Canonical Pathways with Length of Survival in Pulmonary Arterial Hypertension

Webb, A., An, H., Correa-Jaque, P., Lin, S., Liu, Z., Tiwari, H. K., Wiener, H., & Benza, R. L. “Abstract 11344: Association of Canonical Pathways with Length of Survival in Pulmonary Arterial Hypertension.” Circulation, vol. 144, no. Suppl_1, Nov. 2021, pp. A11344–A11344.  Introduction: Pulmonary arterial hypertension (PAH) is a chronic, progressive disease without cure. Treatment can improve […]

CHEST 2021: EKG Parameters In Predicting Survivals In Pulmonary Arterial Hypertension

Kraisangka, J., Scott, J.,  Kanwar, M., Liu, Z., Lin, S., Everett, A., Perer, A., Movahedi, F., Antaki, J., Benza, R. “EKG Parameters In Predicting Survivals In Pulmonary Arterial Hypertension.” Chest, vol. 160, no. 4, Oct. 2021, pp. A2325–26. PURPOSE: EKG parameters are ones of the predictors for prognosis of the patients with pulmonary arterial hypertension (PAH). […]

CHEST 2021: EFFECTIVE COMMUNICATION OF MACHINE LEARNING MODELS IN CLINICAL DECISION SUPPORT TOOLS FOR PAH RISK PREDICTION

Benza, R., Kanwar, M., Antaki, J., Dhabalia, A., Manavalan, M., Xin, Z., Perer, A. “Effective Communication of Machine Learning Models In Clinical Decision Support Tools For PAH Risk Prediction”. Chest, vol. 160, no. 4, Oct. 2021, pp. A1396–97. PURPOSE: Risk-stratification in pulmonary artery hypertension (PAH) is essential to determine prognosis, monitor disease progression, and response […]

ISHLT 2021: Hemodynamic Parameters in Predicting Time to Clinical Worsening in Pulmonary Arterial Hypertension

Kanwar, M. K., Krainsangka, J., Scott, J., Perer, A., Antaki, J., Benza, R. “Hemodynamic Parameters in Predicting Time to Clinical Worsening in Pulmonary Arterial Hypertension.” The Journal of Heart and Lung Transplantation, vol. 40, no. 4, Apr. 2021, p. S189. PurposeHemodynamics are considered to be extremely relevant when clinically assessing patients with PAH, especially for […]

ISHLT 2021: Hemodynamic Parameters in Predicting Survival in Pulmonary Arterial Hypertension

Kanwar, M. K., Krainsangka, J., Scott, J., Barrett, T., Everett, A., Perer, A., Antaki, J., Benza, R. “Hemodynamic Parameters in Predicting Survival in Pulmonary Arterial Hypertension.” The Journal of Heart and Lung Transplantation, vol. 40, no. 4, Supplement, Apr. 2021, p. S188.  PurposeHemodynamics are considered to be extremely relevant when clinically assessing patients with pulmonary arterial […]

ATS: Bayesian Network Modeling: The Future of Pulmonary Arterial Hypertension Risk Stratification Through the PHORA Initiative

Scott JV, Kraisangka J, Kanwar M, Druzdzel M, Antaki J, Vizza D, et al. B97. WHAT’S NEW IN CLINICAL RESEARCH IN PULMONARY HYPERTENSION: LESSONS FROM THE BEST ABSTRACTS: American Thoracic Society; 2020:A4245-A. Introduction: Pulmonary arterial hypertension (PAH) is a fatal and difficult to treat disease due to patient inter-variability. Accurate patient risk stratification is necessary […]

ATS: Pulmonary Arterial Registry Risk Algorithms Improve Upon Clinical Trial Enrichment Methodology

Scott JV, Kanwar M, Garnett C, Stockbridge N, Benza RL. B27. UP-TO-DATE PAH ASSESSMENT AND MANAGEMENT: American Thoracic Society; 2020:A2920-A. Introduction: Pulmonary arterial hypertension (PAH) is a rare disease with poor prognosis. Clinical trials for PAH now use time to morbidity/mortality event (clinical worsening) as the primary endpoint instead of six-minute walk distance (6MWD). These […]